NCT04152148View on ClinicalTrials.gov

A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions
Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

500mg BAT4306F

Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

BIOLOGICAL

750mg BAT4306F

Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

BIOLOGICAL

900mg BAT4306F

Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

BIOLOGICAL

1000mg BAT4306F

Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

Trial Locations (1)

100089

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY